Skip to content

Prognostic Factors in treatment of Functional Childhood Constipation. A multicenter observational cohort study in the Netherlands. (The PROFUNCO Study)

Prognostic Factors in treatment of Functional Childhood Constipation. A multicenter observational cohort study in the Netherlands. (The PROFUNCO Study) - The PROFUNCO Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON41542
Enrollment
Unknown
Registered
2015-08-27
Start date
2016-09-01
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

functional constipation

Interventions

None listed

Sponsors

Maasstadziekenhuis
Lead Sponsor

Eligibility

Age
2 Years to 17 Years

Inclusion criteria

Inclusion criteria: Functional Childhood Constipation in children under the age of 4 (Rome III criteria (31): Must include 1 month of at least 2 of the following in infants up to 4 years of age: 1. Two or fewer defecations per week, 2. at least 1 episode per week of incontinence after the acquisition of toileting skills, 3. History of excessive stool retention, 4. History of painful or hard bowel movements, 5. Presence of a large fecal mass in the rectum, 6. History of large-diameter stools that may obstruct the toilet*. Functional Childhood constipation in a child with a developmental age of at least 4 years with insufficient criteria of IBS (Rome III criteria): Must include 2 or more of the following: 1. Two or fewer defecations per week, 2. at least one episode of fecal incontinence per week, 3. Stool retentive posturing, 4. Painful or hard bowel movements, 5. Large diameter stools that could obstruct the toilet, 6. Presence of a large fecal mass in the abdomen or rectum. Age 0 - 16 years. Written informed consent by both parents and/or by patient in the age of 12-18 years.

Exclusion criteria

Exclusion criteria: Children with organic cause of constipation: Hirschsprung*s disease, anorectal malformations, neuronal intestinal dysplasia, Spinal cord abnormalities, spinal cord trauma, neurofibromatosis, tethered cord, Hypothyroidism, diabetes mellitus, hypercalcemia, hypokalemia, vitamine D intoxication, Drug use: opoids, anticholinergic agents, antidepressants, Anorexia nervosa, sexual abuse, cystic fibrosis, dietary protein allergy. Age above 18 years

Design outcomes

Primary

MeasureTime frame
A sustained response to treatment 6 months after start of treatment, defined as: the patient having a stool frequency of at least three times weekly, without fecal incontinence. Sustained response is defined as successfully treated as defined above in the absence of relapse of symptoms, and irrespective of laxative treatment. At 6 months patients are considered either responder or non-responder to therapy.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)